All articles tagged with #immunoglobulin a nephropathy
Omeros' drug candidate for immunoglobulin A nephropathy (IgAN) failed a Phase III study, causing the company's stock price to drop by nearly half. The late-stage failure is a setback for Omeros' pipeline-in-a-product plans for narsoplimab, and as a result, the ARTEMIS-IGAN study will be discontinued. The trial did not achieve statistical significance in reducing elevated protein levels in urine compared to the placebo.
A study by Columbia University researchers has identified 16 genetic sites associated with immunoglobulin A (IgA) nephropathy, a common kidney disease. The findings suggest that the disease's source is external to the kidney and involves the immune system. This discovery opens up new possibilities for detecting, managing, and treating IgA nephropathy. The study, which involved nearly 40,000 participants and took 10 years to complete, is the largest ever on the genetics of IgA nephropathy. The identified genes are involved in the production of IgA antibodies, highlighting the importance of regulating IgA levels in the disease. The researchers also identified potential drug targets and existing drugs that may be repurposed for IgA nephropathy treatment.